Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
EMC$33.86-0.28(-0.82%)EMC Insurance Receives Insurity's Excellence in Operational Efficiency Award[12:01:00 PM ET]SWMR$9.06+0.54(+6.28%)Swarmer to Host Investor Call to Discuss Acquisition of Ratel Robotics[12:00:00 PM ET]CMCSA$22.09-0.61(-2.67%)Comcast Completes Construction in Tulare County, Connecting Thousands to High-Speed Internet for the First Time[12:00:00 PM ET]GCDT$0.14-0.04(-20.84%)Green Circle Decarbonize Technology Limited Issues Statement Regarding Unusual Market Activity[11:45:00 AM ET]KLAR$12.62-0.19(-1.48%)Klarna's flexible payment options now available at Adorama, giving creators more ways to fuel their next project Adorama, a leading photography, video, audio, drone, and computer retailer, and Klarna, the everyday finance network, today announced that Klarna is...[11:39:00 AM ET]DUK$124.56-0.42(-0.34%)Duke Energy Florida shares tips for warding off energy vampires, saving money This Halloween, Duke Energy Florida is reminding customers of the scary reality of energy "vampires" – appliances and electronics lurking throughout...[11:39:00 AM ET]FFR$1.08-0.05(-4.87%)FF EAI Robotics Ecosystem Completed its Acquisition of the Robotics Business of Faraday Future, Establish Nasdaq-Listed Humanoid and Bionic Robotics Platform FF EAI Robotics Ecosystem Inc. ("FFR") (NASDAQ: FFR), a U.S.-based Embodied AI robotics company, and Faraday Future Intelligent Electric Inc....[11:30:00 AM ET]MRK$141.92-3.36(-2.31%)Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer[11:30:00 AM ET]FFR$1.08-0.05(-4.87%)Faraday Future Announces Completion of FF EAI Robotics Ecosystem's (FFR) Acquisition of Faraday Future's Robotics Business and Establishment of a Nasdaq-Listed Humanoid and Bionic Robotics Platform[11:30:00 AM ET]STGW$8.66-0.33(-3.62%)Stagwell (STGW) Acquires Freestar, Leading Publisher Advertising Services Company[11:30:00 AM ET]PGNY$28.40-0.57(-1.97%)New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model[11:25:22 AM ET]

VKTX · NASDAQ

Viking Therapeutics, Inc.

$24.29 -0.11 (-0.45%)

Company overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRβ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRβ for X-linked adrenoleukodystrophy.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$3.1B
Employees
45
Headquarters
San Diego, CA
Website
vikingtherapeutics.com
CEO
Brian Lian
Listed
April 28, 2015
P/E
-5.87
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$208,000
Operating income
-$502M
EBITDA
-$502M
Net income
-$472M
EPS
-$4.14
Total assets
$608M
Total debt
$0.00
Earnings yield
-17.04%

Price chart

23.6128.6733.7338.7943.85
VKTX 1D NASDAQ O25.54H25.74L24.36C24.40-1.43 (-5.54%)Vol4.68M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Type
Ticker Type Headline Source Published
VKTXViking Therapeutics, Inc. Stock news Should You Buy Viking Therapeutics Stock Ahead of Q3 Results? Zacks Investment Research
VKTXViking Therapeutics, Inc. Stock news Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28 24/7 Wall Street
VKTXViking Therapeutics, Inc. Stock news Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market Zacks Investment Research
VKTXViking Therapeutics, Inc. Stock news Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know Zacks Investment Research
VKTXViking Therapeutics, Inc. Stock news NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains? Zacks Investment Research
VKTXViking Therapeutics, Inc. Press release Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026 Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for... PR Newswire
VKTXViking Therapeutics, Inc. Stock news Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. The Motley Fool
VKTXViking Therapeutics, Inc. Stock news Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know Zacks Investment Research
VKTXViking Therapeutics, Inc. Stock news Viking Therapeutics Starts Phase III Development of Obesity Pill Zacks Investment Research
VKTXViking Therapeutics, Inc. Stock news Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? Zacks Investment Research
VKTXViking Therapeutics, Inc. Press release Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity Viking Therapeutics, Inc. PR Newswire
VKTXViking Therapeutics, Inc. Stock news Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. The Motley Fool
VKTXViking Therapeutics, Inc. Stock news Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? Fool - Investing News
VKTXViking Therapeutics, Inc. Stock news VKTX Advances Obesity Program With New Oral Maintenance Study Zacks Investment Research
VKTXViking Therapeutics, Inc. Stock news VKTX Down 16% in a Month: Time to Invest or Exit the Stock? Zacks Investment Research
VKTXViking Therapeutics, Inc. Stock news Here Are My Top 4 Stocks to Buy in October Fool - Investing News
VKTXViking Therapeutics, Inc. Stock news Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price? The Motley Fool
VKTXViking Therapeutics, Inc. Stock news Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors Zacks Investment Research
VKTXViking Therapeutics, Inc. Stock news Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy Fool - Investing News
VKTXViking Therapeutics, Inc. Stock news Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts Zacks Investment Research
See more
FAQ

Questions about Viking Therapeutics, Inc.

What does Viking Therapeutics, Inc. do?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRβ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRβ for X-linked adrenoleukodystrophy.
What is VKTX's market cap?
Viking Therapeutics, Inc. (VKTX) is a listed stock with a live quote. The latest market cap on this page is $3.1B.
Where is Viking Therapeutics, Inc. headquartered?
Viking Therapeutics, Inc. is headquartered in San Diego, CA.
How do I get VKTX news from the API?
Call GET /v1/news?tickers=VKTX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does VKTX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for VKTX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the VKTX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs